# Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients

> **NCT02321709** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 21 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** SAR113244
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02321709
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02321709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02321709, "Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02321709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*